Statistical Considerations for Surrogate Endpoints Mark Rothmann* Minimal Residue Disease in AML Workshop March 4, 2013 *The views expressed in this presentation are those of the presenters and - Rothmann - Document - PDFSEARCH.IO

First Page	Meta Content
	Statistical Considerations for Surrogate Endpoints Mark Rothmann* Minimal Residue Disease in AML Workshop March 4, 2013 The views expressed in this presentation are those of the presenters and Add to Reading List Open Document File Size: 128,79 KB Share Result on Facebook Facility Robert Temple / / MedicalCondition Surrogate Endpoints Mark Rothmann Minimal Residue Disease / HIV / disease / / Organization U.S. Food and Drug Administration / National Institute of Health / / Person Mark Rothmann / Thomas Fleming / / SocialTag Health Clinical trials Clinical research Medical research Medical terms Surrogate endpoint Clinical endpoint Biomarker Randomized controlled trial Medicine

Statistical Considerations for Surrogate Endpoints Mark Rothmann* Minimal Residue Disease in AML Workshop March 4, 2013 *The views expressed in this presentation are those of the presenters andAdd to Reading List